Fallübersicht

In a swift resolution that underscores the strength of pharmaceutical patent enforcement under the Hatch-Waxman framework, Galderma Laboratories and its affiliated entities secured a **consent judgment and permanent injunction** against Taro Pharmaceuticals, Inc. in the U.S. District Court for the District of New Jersey. The case, filed January 19, 2024, and closed July 8, 2024—a remarkably efficient 171-day lifespan—centered on two patents protecting **trifarotene cream (0.005%)**, a fourth-generation topical retinoid approved for acne vulgaris treatment.

The outcome signals the continued robustness of innovator patent positions in the topical dermatology space and offers critical strategic lessons for pharmaceutical patent attorneys, IP professionals managing ANDA-related portfolios, and R&D teams navigating freedom-to-operate analysis in the retinoid market. For any practitioner tracking **pharmaceutical patent infringement** litigation in New Jersey, this case is a benchmark for how quickly a well-positioned innovator can convert infringement claims into durable injunctive relief.

Die Parteien

Die streitigen Patente

Two U.S. patents formed the foundation of Galderma’s infringement action, protecting core intellectual property surrounding trifarotene, a selective RAR-γ agonist differentiated from earlier retinoid generations. These patents are registered with the U.S. Patent and Trademark Office (USPTO).

• • US9498465B2 — Covers formulation and composition claims related to trifarotene-based topical preparations.
• • US9084778B2 — Covers related aspects of the trifarotene compound and its therapeutic use in topical application.

Das Urteil und die rechtliche Analyse

Ergebnis

The case terminated by **Consent Judgment and Order of Permanent Injunction**—a dispositive resolution in which both parties agreed to the entry of a court order without a contested trial. The specific financial terms were not publicly disclosed. However, the grant of **permanent injunctive relief** is the operative outcome: Taro is enjoined from commercializing its generic trifarotene cream (0.005%) product in a manner that infringes the asserted patents for the duration of their enforceability.

Wichtige rechtliche Fragen

The verdict cause is categorized as an **infringement action**, consistent with a Paragraph IV ANDA challenge. In this context, Galderma alleged that Taro’s filing of an ANDA seeking approval for a generic trifarotene cream constituted a technical act of infringement under 35 U.S.C. § 271(e)(2). The consent judgment suggests Taro did not successfully mount invalidity or non-infringement defenses sufficient to avoid an agreed resolution favoring Galderma’s patent position.

This early resolution, within 171 days, implies that Taro could not demonstrate the asserted claims of US9498465B2 or US9084778B2 were invalid, nor could it effectively design around the asserted claims. The resolution avoids the cost and uncertainty of Markman hearings and expert-intensive validity disputes, preserving resources for both parties while establishing an enforceable injunction.